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INTRODUCTION
One of the most common respiratory diseases 
in horses is recurrent airway obstruction (RAO). 
The term derived from human medicine Chronic 
Obstructive Pulmonary Disease (COPD), has not 
been used since the late 1990s. This disease is 
encountered in horses older than 7 years, that are 
kept in stables, standing on straw bedding and fed 
poor-quality hay (1). So far, no breed predisposition 
to the disease has been found; however, genetic 
background should be taken into account, as more 
frequent cases of the disease have been described in 
certain breeding lines.
PATHOGENESIS
The development of the disease involves two 
types of allergic reactions: type I in an initial stage 
and type III in a later stage (2). Airway inflammation 
in horses predisposed to RAO is caused by inhalation 
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of organic pollutants contained in dust, the largest 
source of which are hay and bedding. Endotoxins, 
dust mites and fungal spores contained in the dust, 
such as Feaniarecti virgula, Aspergillus fumigatus, 
Thermoactinomyces vulgaris, on entering the 
airways activate inflammatory cytokine production 
and neutrophil influx into the lumen of the bronchi 
(3). When an animal is led from the pasture to the 
stable and exposed to allergens, inflammatory 
changes occur within 6-8 hours. As inflammation 
develops, lower respiratory tract stricture increases. 
Inflammatory mediators are responsible for 
bronchoconstriction that causes both smooth muscle 
contraction acting on their cholinergic endings, as 
well as a large amount of mucus to accumulate in 
the bronchi as a result of goblet cells hyperplasia 
(Fig. 1). The mucus is denser and less transparent 
than that produced under physiological conditions. 
This makes it difficult to remove secretions and 
leads to prolonged retention in the airway lumen. 
Reconstruction of the bronchial walls involves both 
acute (intercellular edema) and chronic (smooth 
muscle hypertrophy, peribronchial fibrosis) changes 
(4). Changes in the airway wall are due to chronic 
processes and the lower effectiveness of the therapy 
and often make it impossible to return the animal to 
its normal condition.
Although the condition has an allergic 
background, eosinophils do not play a significant 
role in the pathogenesis of RAO. 
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CLINICAL SYMPTOMS
The initial stage of RAO is difficult to diagnose. 
Non-specific symptoms in the form of single 
coughing attacks may suggest a number of other 
diseases. At a later stage, the frequency of the dry 
cough, often paroxysmal in nature, increases.
RAO exacerbation is manifested by an increase 
in the respiratory rate, a frequent cough, nostril 
dilatation, mucosal nasal discharge and exercise 
intolerance (Fig. 2). Severe symptoms usually occur 
during exercise or are associated with an increase 
in the amount of dust in the air (e.g. while cleaning 
the stable or feeding hay). In horses suffering from 
chronic disease, a two-phase process of exhaling 
supported by the abdominal muscles is observed. 
This results in hypertrophy of the external abdominal 
oblique muscle, which manifests itself as a so-called 
“heave line” (Fig. 3).
In advanced untreated cases, the intake of food 
by the horse can be reduced, which leads to weight 
loss and devastation of the animal’s organism. At 
the same time, a pale coloration of the mucous 
membranes or, in extreme cases, cyanosis may 
appear. In the area of the foreskin or mammary 
gland congestive edema is observed, and exhalation 
is accompanied by a pushing of the anus. Each 
time the animal is used for work it causes fatigue 
disproportionate to the effort.
Figure 1. The bronchoconstriction with large amount of 
mucus accumulated in the bronchi as a result of goblet 
cells hyperplasia
Figure 2. Nostril dilatation and mucosal nasal discharge 
in RAO
Figure 3. Hypertrophy of the external abdominal oblique 
muscle which manifests itself as a so-called  “heave line”
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In a horse at rest, auscultation of the lungs 
in the early stages of the disease will not reveal 
any pathological changes. During the effort test, 
wheezing and rattling coming from the peripheral 
lung can be heard. 
DIAGNOSTICS 
The diagnosis of advanced RAO involves 
mainly a history and characteristic clinical signs. 
In the early stage of the disease additional tests 
are required. A blood test is helpful in excluding 
pneumonia and other infectious diseases, because in 
the course of RAO blood parameters do not deviate 
from the reference values (5).
A useful examination showing the state of the 
cellular inﬁ  ltration of the lung is bronchoalveolar 
lavage (BAL). In cytological preparations made 
from the ﬂ   uid, the largest group of cells are 
non-degenerated neutrophils (15-85% of all cells), 
whereas in healthy horses there are no more than 
10% (6). There are also a number of compact 
formations of bronchial mucus (Curschmann’s 
spirals). Neutrophil count positively correlates with 
the severity of lesions and the course of the disease.117
Radiological examination (X-ray) of the lung 
is helpful in a differential diagnosis. It is used to 
rule out other diseases of the lower respiratory 
tract. Lesions imaged using an X-ray are not 
pathognomonic for RAO, while on a radiograph 
only fibrosis of the lung parenchyma can be seen. 
By using a bronchoscope, tracheal wall congestion, 
tracheal bifurcation (bifurcatio tracheae) and 
residual mucous can be confirmed (1, 7).
An examination evaluating the severity of 
lesions and their susceptibility to therapy is the 
determination of the acid-base balance of arterial 
blood. The most decisive parameters are the partial 
pressure of oxygen (PaO2) and carbon dioxide 
(PaCO2). PaO2 falls a lot below 80 mmHg in 
animals with the initial form of the disease and up 
to 50 mmHg in horses with advanced RAO. PaCO2 
usually does not deviate from the reference value or 
is slightly elevated (5).
For RAO staging, the author correlates clinical 
(CS) and endoscopic (ES) scores in horses with 
RAO (Table 1).
TREATMENT
Modification of the environment
The best method of treatment of recurrent 
airway obstruction in horses is a modification 
of the environment, which leads to a decrease 
in air aeroallergens. Pharmacological therapy of 
RAO includes treatment with glucocorticoids and 
bronchodilators. This procedure should involve both 
horses with advanced disease, as well as animals 
with a slight exacerbation of clinical symptoms. 
Pharmacological treatment without environmental 
modification is not effective (8).
Parameter 01 2 3 4 5
Clinical 
assessmenta
Cough score None
Coughs at speciﬁc 
times
of day (feeding/
exercising/making 
beds)
Frequent cough 
with periods of no 
coughing
Very frequent cough
Nostril ﬂ  are None
Flares during 
inspiration
(returns to normal 
at end
inspiration)
Flares in inspiration 
and exhalation (slight 
movement can still be 
seen)
Flares in inspiration 
and expiration (no 
movement can be 
seen)
Abdominal lift None Slight ﬂattening of
ventral ﬂank
Obvious abdominal 
ﬂattening and ‘‘heave
line’’ extending no 
more than half way
between the cubital 
joint and tuber coxae
Obvious abdominal 
lift and ’’heave line’’
extending beyond 
halfway between
the cubital joint and 
tuber coxae
Airway 
endoscopyb
Mucus 
accumulation
None, 
clean
Little, multiple 
small
blobs
Moderate, larger 
blobs
Marked, conﬂuent or 
stream-forming
Large, 
pool-
forming
Extreme,
profuse
amounts
Mucus color None, 
clean Colorless White Thick White Yellow Thick
Yellow
Mucus 
localization 
and stickiness
None, 
clean 1/2 Ventral 2/3 Lateral 3/4 Dorsal Threading Threading
Mucus 
apparent 
viscosity
None, 
clean Very ﬂuid Fluid Intermediate Viscous Very
viscous
Table 1. Modified clinical staging of RAO in horses according to Tilley et al. (17)
aFinal Clinical Score (CS): 0 (CS ﬁnal score < 2); 1 (2 ≤ CS ﬁnal score ≤ 4); 2 (5 ≤ CS ﬁnal score ≤ 6); 3 (7 ≤ CS ﬁnal score ≤ 9)
bFinal Airway Endoscopy Score: 0 (ES ﬁnal score < 8.5); 1 (8.5 ≤ ES ﬁnal score ≤ 12); 2 (12 < ES ﬁnal score ≤ 16); 3 (ES ﬁnal 
score > 16)
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Drug Drug  family Dose Notes 
Dexamethasone Corticosteroid 0,05-0,1 mg/kg
q24h
p.o., 
i.v., i.m.
Reduces airway obstruction and inﬂammation 
within 3 to 7 days, with clinical beneﬁt evident 
for up to 7 days.
Prednisolone Corticosteroid 2,2 mg/kg 
q24h
p.o. Expensive. Good absorption form gastrointestinal 
tract.
Triamcinolone Corticosteroid 0,09 mg/kg i.m. Single dose relieves lower airway obstruction for 
up to 4 weeks. Results in adrenal suppression for 
up to 6 weeks.
Beclomethasone Corticosteroid 500-1500 μg/
horse
q12 h
inhalation Clinical improvement is apparent approx. 24 
hours after initiation of therapy.
Fluticasone Corticosteroid 2000 μg/
horse
 q12h
inhalation Expensive. Most potent with the advantage of 
the lowest adreno suppressive effects. Highly 
lipophilic, resulting in the longest pulmonary 
residence time.
Ipratropium
bromide
Anticholinergic 210-360 μg/
horse
q6h 
inhalation Improves pulmonary function by 50% within 1 
hour, duration of effect is approx. 4 to 6 hours.
Albuterol β2-agonist 360-720 μg/
horse
q3h
inhalation Rescue therapy. Improves pulmonary function by 
70% within 5 minutes of administration.
Clenbuterol β2- agonist 0,8-3,2 μg/kg
q12h
p.o., 
i.v.
IV (low dose only). Very effective.
Salmeterol β2- b2-agonist 60-210 μg/
horse
q 8h
inhalation Improves pulmonary function within 60 minutes 
of administration, with efficacy lasting for up to 
8 hours.
Table 2. Drugs commonly used in RAO treatment 
The best solution is year-round maintenance 
of the animal in pasture. This is possible in almost 
every climate, because horses can withstand 
temperatures down to -30ºC without any health 
consequences. Only during frosts should they be 
provided with a winter shelter and fed high quality 
food. Remission of clinical symptoms is noticed 
after about 3-4 weeks from the time of moving the 
horse from the stable to the pasture (9,10). Repeated 
contact with the stable environment should then be 
avoided, because even a few minutes’ of exposure
to the contaminants contained therein may cause
a recurrence of the disease. If the therapy is 
unsuccessful, it should be carefully checked 
whether horses are being maintained in accordance 
with the recommendations. It often happens that the 
horses are brought into the stables at night or during 
feeding.
If for some reasons the owner is not able 
to provide an animal with such conditions, the 
treatment should be carried out within the stable. 
Since the feed is one of the main sources of dust, 
special attention should be paid to its quality. If it 
is not possible to provide adequate quality hay, it 
should be soaked before use in water and put in a 
hay net. Merely sprinkling it is not enough, because 
the water quickly evaporates from the surface and 
does not penetrate into the deeper layers (11). A 
good, but expensive solution is keeping the hay in 
silos or feeding a complete pelleted hay. However, 
in the former case the horse owner needs to use 
the appropriate silos due to the high sensitivity of 
horses to botulism.
To improve the conditions of maintenance, it is 
necessary to change the type of bedding. Keeping 
the horse on straw, which is most commonly used, 
Niedźwiedź A.
Final RAO Stage: Stage 0 – No RAO (Total Score = 0 ); Stage 1 – Mild RAO (1 ≤ Total Score < 2); Stage 2 – Moderate RAO
(3 ≤ Total Score ≤ 4); Stage 3 – Severe RAO (5 ≤ Total Score = 6)119
significantly increases the amount of dust in the 
stable. Sawdust, peat, paper or cardboard can be 
used as straw replacements. This increases the cost 
of maintenance; however, it brings good results. 
The factor that has a major impact on air quality in 
the stable is ventilation. Five air changes per hour in 
the stable are sufficient to significantly reduce the 
amount of dust in the air (12).
Modifying the environment must involve 
the entire stable to be effective. This is the only 
way that, in cooperation with pharmacological 
therapy, respiratory system functions may improve 
sufficiently to allow the horse to live normally. 
Pharmacological therapy
RAO treatment involves the simultaneous 
use of corticosteroids and bronchodilators 
(Table 2). Steroids reduce airway inflammation 
and bronchodilators improve bronchial airﬂ  ow. 
Bronchodilators are not recommended for use as 
the sole therapy, because they do not exert any anti-
inflammatory activity. Due to the synergistic effect 
of these drugs and the possibility of side effects, one 
should not exceed the recommended dose (13). 
Non-steroidal anti-inflammatory drugs 
(NSAIDs) and antihistamines are not applicable in 
the treatment of RAO.
Corticosteroids may be administered 
systemically or inhaled. The first solution is cheaper 
and simpler to be implemented, but long-term use 
entails the risk of iatrogenic Cushing’s syndrome. 
Systemic drugs are generally recommended for 
horses with severe respiratory ailments, since 
in these cases inhalants have limited access to 
the airways. In cases with mild symptoms, it is 
recommended to use corticosteroids inhaled using 
a special inhalation masks (Equine AeroMask 
or Equine Haler). Drugs used via inhalation act 
directly on the lower respiratory tract, which means 
that their doses are not high. Such treatment is very 
effective and usually there are no side effects, but 
this increases the cost of treatment (14,15).
Short-acting, inhaled bronchodilators are used 
in severe, life-threatening cases. Properly applied, 
they improve breathing as soon as 5 minutes after 
administration and their effect is maintained for 
about one hour. Long-acting bronchodilators 
are used for the prevention of exercise-induced 
bronchospasm or that from contact with a dusty 
stable environment (16). It should be noted, 
however, that the rules and regulations used in the 
majority of equestrian competitions and shows do 
not allow the use of these drugs before taking part 
in competition.
CONCLUSION
The prognosis for RAO is only good if the 
disease is diagnosed early, the appropriate treatment 
is introduced and the owner can provide the animal 
with an environment devoid of sensitizing allergens. 
On starting treatment, one should also take into 
account the high cost and long-term nature of the 
therapy and the possibility of the recurrence of the 
disease in the case of horse exposure to an adverse 
environment. Adequate conditions will enable the 
normal use of the animal for many years.
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